TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25790835
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injections at postoperative days 7 and 14
Study: 20420283
Drug: Dinoprostone vaginal
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone vaginal insert (10 mg for 12 hours)
Study: 20420283
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (20 IU during cesarean delivery)
Study: 16803851
Drug: Bromocriptine (D2R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (D2R agonist)
Study: 10637064
Drug: Intraperitoneal cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal cisplatin (50 mg/m²) plus intravenous epidoxorubicin (60 mg/m²) and intravenous cyclophosphamide (600 mg/m²)
Study: 10637064
Drug: Intravenous cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisplatin (50 mg/m²) plus intravenous epidoxorubicin (60 mg/m²) and intravenous cyclophosphamide (600 mg/m²)
Study: 8892457
Drug: CY/TBI (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: CY/TBI (120 mg/kg cyclophosphamide and 1320 cGy total body irradiation)
Study: 8892457
Drug: BU/CY (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: BU/CY (16 mg/kg Busulfan and 200 mg/kg cyclophosphamide)
Study: 6607245
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose CMFVP
Study: 6607245
Drug: Three drug
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three drug combination CAF (doxorubicin)
Study: 6607245
Drug: CAMELEON (sequentially
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMELEON (sequentially alternating therapy) added to CAF
Study: 6607245
Drug: Aggressive combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive combination chemotherapeutic approaches
Study: 11275859
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care and ibuprofen
Study: 9113182
Drug: esmolol 1
Normalized name: esmolol 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol 1 mg.kg‐1 + 200 micrograms.kg‐1.min‐1
Study: 2660557
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g three times a day
Study: 7816004
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice only (without K- and Mg-phosphate supplementation)
Study: 7816004
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice with K- and Mg-phosphate supplementation
Study: 28240625
Drug: In SHAPE
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In SHAPE program (gym membership, weekly individual meetings with a fitness trainer, instruction on healthy eating and nutrition)
Study: 25648347
Drug: FMI tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMI tablet (500 mg)
Study: 25648347
Drug: HF meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF meal (with FMI tablet 300 mg)
Study: 25648347
Drug: LF meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: LF meal (with FMI tablet 300 mg)
Study: 25648347
Drug: NM (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: NM (with FMI tablet 300 mg)
Study: 24463669
Drug: Nitrofurantoin 100
Normalized name: nitrofurantoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin 100 mg once daily during catheterization
Study: 19620077
Drug: Hypofractionated radiotherapy
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiotherapy at 3.0 Gy/fraction (30 Gy total) combined with weekly docetaxel at 60 mg for 2 weeks
Study: 11474385
Drug: Routine sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine sedation with midazolam (0.07 mg/kg) and meperidine (0.77 mg/kg)
Study: 3291895
Drug: nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 30 mg po
Study: 31538488
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support intervention (6-weekly visits from a peer support worker in addition to routine care)
Study: 26482148
Drug: Cherry juice
Normalized name: Cherry Juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cherry juice (200 ml/day)
Study: 22290680
Drug: iv lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv lornoxicam (8 mg)
Study: 22290680
Drug: iv paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv paracetamol (1 g)
Study: 22290680
Drug: iv saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv saline solution (Control)
Study: 10980880
Drug: Systemic anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic anticoagulation therapy
Study: 3967455
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg amantadine)
Study: 3967455
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg amantadine
Study: 3967455
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg amantadine
Study: 29588170
Drug: Lira‐basal (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lira‐basal (0.9 mg/day liraglutide plus basal insulin)
Study: 29588170
Drug: BBIT (basal-bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBIT (basal-bolus insulin therapy)
Study: 28472303
Drug: Whole Body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Body Vibration (WBV) training (3 × 3 minutes twice daily for 5 months)
Study: 25445405
Drug: Tripterygium wilfordii
Normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium wilfordii Hook. f. (TwHF) 1.5 mg/kg/day
Study: 25445405
Drug: Azathioprine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine 2.0 mg/kg/day
Study: 14696664
Drug: Implant-retained overdenture
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant-retained overdenture (IRO)
Study: 14696664
Drug: Endosseous implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endosseous implants
Study: 8697067
Drug: Orlistat 10
Normalized name: orlistat 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 10 mg, 60 mg, and 120 mg three times a day
Study: 1781526
Drug: Adrenaline 1:200,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline 1:200,000 administered 5 minutes before 20 ml bupivacaine 0.5%
Study: 1781526
Drug: Saline followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline followed by 20 ml bupivacaine 0.5% with 100 micrograms adrenaline
Study: 1781526
Drug: Saline followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline followed by 20 ml plain bupivacaine 0.5%
Study: 7014790
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group (5 mg/kg/day of methylprednisolone)
Study: 7014790
Drug: Nonsteroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroid group (no drug)
Study: 30304936
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (comprehensive discharge planning, offering substance abuse treatment, provision of information on self-scheduling appointments).
Study: 25503600
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal system (BTDS) 5, 10, and 20 μg/h (maximum dosage of 20 μg/h)
Study: 25503600
Drug: Sustained-release tramadol
Normalized name: tramadol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tramadol tablets 100 mg (maximum dosage of 400 mg/d)
Study: 23792641
Drug: PF-3512676 (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-3512676 (0.20 mg/kg injected subcutaneously once weekly) plus erlotinib (150 mg daily)
Study: 23792641
Drug: erlotinib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: erlotinib alone (150 mg daily)
Study: 19762706
Drug: Conventional, stepwise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional, stepwise fever management with anti‐inflammatory drugs and surface cooling
Study: 15204145
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 microg/g ointment twice daily for 12 weeks
Study: 15204145
Drug: Betamethasone 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone 0.1% ointment twice daily for 12 weeks
Study: 9648983
Drug: Control (full-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (full-dose ranitidine for 3 weeks)
Study: 2019185
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg qid)
Study: 2019185
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (40 mg bid)
Study: 7046974
Drug: IV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV and oral metoclopramide
Study: 23530576
Drug: Acarbose 50 mg
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 50 mg once daily plus isophane protamine biosynthetic human insulin 70/30 injections twice daily 30 min before meals (Group A)
Study: 23530576
Drug: Acarbose 50 mg
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 50 mg three times daily plus isophane protamine biosynthetic human insulin 70/30 injections twice daily immediately before meals (Group C)
Study: 23530576
Drug: Acarbose 50 mg
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 50 mg three times daily plus isophane protamine biosynthetic human insulin 70/30 injections twice daily 30 min before meals (Group B)
Study: 21521342
Drug: Hydrocortisone regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone regimen C (10 mg mane/5 mg tarde)
Study: 21521342
Drug: Hydrocortisone regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone regimen A (20 mg mane/10 mg tarde)
Study: 21521342
Drug: Hydrocortisone regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone regimen B (10 mg mane/10 mg tarde)
Study: 21521342
Drug: Hydrocortisone regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone regimen C (10 mg/5 mg)
Study: 18922087
Drug: Polychromatic visible
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polychromatic visible (pVIS) light exposure (385-750 nm, 95% polarization, 40 mW/cm2, 12 J/cm2) with NOS inhibitor (L-NMMA, 0.1% solution) administered iontophoretically prior to exposure
Study: 18922087
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with NOS inhibitor (L-NMMA, 0.1% solution) administered to the non-irradiated hand
Study: 16217756
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 mcg of selenized yeast)
Study: 12946034
Drug: Aspirin (more
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (more than 325 mg per day)
Study: 6132935
Drug: Lorazepam (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1.0 mg)
Study: 6132935
Drug: Alcohol (1/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1/6 or 1/2 gill of vodka, equal to 6.5 or 19.6 g)
Study: 6132935
Drug: Lorazepam (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1.0 mg) + Alcohol (1/6 or 1/2 gill of vodka)
Study: 25218194
Drug: AERAS-402 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: AERAS-402 (single dose)
Study: 15218298
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 i.v. over 1 h followed by gemcitabine 2,000 mg/m2 biweekly until progression or intolerable toxicity
Study: 1124050
Drug: 2 puffs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs of Sch 1000 administered 6 times
Study: 23343798
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (100U in 10 mL) via cystoscopy
Study: 9250256
Drug: Pranlukast 337.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast 337.5 mg b.i.d.
Study: 9250256
Drug: Pranlukast 450
Normalized name: pranlukast
DrugBank: Pranlukast (DB01411)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Pranlukast 450 mg b.i.d.
Study: 8502270
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (6 g of oil per day, containing 5 g of eicosapentaenoic and docosahexaenoic acid)
Study: 28710873
Drug: Mecamylamine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine 10 mg per day
Study: 26955311
Drug: Precaine gel
Normalized name: proparacaine hydrochloride Ophthalmic Solution [Eyecaine]
DrugBank: Cinchocaine (DB00527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Precaine gel
Study: 26955311
Drug: Benzocaine topical
Normalized name: benzocaine topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine topical paste
Study: 26955311
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no topical anesthetic)
Study: 8699873
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) infusion (1,200 mg)
Study: 1969870
Drug: Astemizole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (10 mg/day)
Study: 30362375
Drug: Lurbinectedin and
Normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lurbinectedin and doxorubicin combination
Study: 30362375
Drug: Standard-of-care chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care chemotherapy (investigator's choice of cyclophosphamide/doxorubicin/vincristine or topotecan)
Study: 25593135
Drug: Aggressive medical
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive medical management therapy (AMM)
Study: 25593135
Drug: Percutaneous transluminal
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous transluminal angioplasty and stenting plus aggressive medical therapy (PTAS)
Study: 19014751
Drug: Olanzapine (5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5‐20 mg/day)
Study: 17531327
Drug: Lithium (600‐1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (600‐1800 mg/day)
Study: 16487090
Drug: Narrow-band ultraviolet
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band ultraviolet B (NB-UVB) phototherapy + tacalcitol ointment
Study: 10861151
Drug: Mechanical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical stimulation of the larynx (L)
Study: 10861151
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 4% lidocaine
Study: 10861151
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine 1 mg/kg
Study: 9202565
Drug: Intracavernosal self-injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal self-injection therapy
Study: 1528093
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg nalbuphine
Study: 1528093
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg morphine
Study: 2859273
Drug: Trimipramine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine 150 mg/day
Study: 10807491
Drug: Maprotiline 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline 150 mg/day
Study: 21244763
Drug: Oral CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CsA 5 mg/kg/day for two consecutive days/week for 24 weeks
Study: 21244763
Drug: Oral CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CsA 5 mg/kg/day
Study: 12626887
Drug: 40 mg/d
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/d prednisone as an adjunct to antiretroviral therapy
Study: 10668714
Drug: Apomorphine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine 0.05 mg/kg subcutaneously
Study: 9132322
Drug: Flurbiprofen LAT
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen LAT patches (40 mg, replaced every 12 hours)
Study: 9132322
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium tablets (50 mg b.d.)
Study: 8458364
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nifedipine and diltiazem
Study: 29193016
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg weekly + TCS
Study: 29193016
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 2 weeks + TCS
Study: 29193016
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (qw + TCS, q2w + TCS, placebo + TCS)
Study: 22248038
Drug: Flibanserin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 50 mg
Study: 9112355
Drug: HLA-B2702-derived peptide
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA-B2702-derived peptide (7 mg/kg)
Study: 8401617
Drug: OFL: 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFL: 400 mg per os (n = 95)
Study: 8401617
Drug: CTRX: 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTRX: 1 g intramuscularly (n = 96)
Study: 2947710
Drug: Folium Sennae
Normalized name: Sennae folium
DrugBank: Senna leaf (DB15889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folium Sennae administered orally
Study: 2947710
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional medicine; Cimetidine and Rheum officinale)
Study: 29263227
Drug: Conventional sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional sequential recording
Study: 27570447
Drug: Evogliptin, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evogliptin, 5 mg od for 7 days (EVO)
Study: 27570447
Drug: Metformin IR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin IR, 1,000 mg bid for 7 days (MET)
Study: 27570447
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EVO and MET (EVO + MET)
Study: 17919608
Drug: Oral or
Normalized name: Doral Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or vaginal estroprogestative contraception
Study: 8855809
Drug: LPS (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS (2 ng/kg) + hydrocortisone (3 micrograms/kg.min) for 6 h before LPS injection
Study: 6841130
Drug: Special dietary
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special dietary counseling and supplements of Sustagen or Isocal
Study: 6841130
Drug: No special
Approvals — FDA: no, EMA: no, PMDA: no
Description: No special advice or supplements (Control)
Study: 16837885
Drug: Ground flaxseed
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ground flaxseed muffins (25 g, 50 mg lignans)
Study: 16837885
Drug: Soy flour
Normalized name: soy flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy flour muffins (25 g, 42 mg isoflavones)
Study: 10933649
Drug: Dirithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dirithromycin (500 mg daily for 5 days)
Study: 8360133
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg bd
Study: 8360133
Drug: Cefaclor 500
Normalized name: cefaclor 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 500 mg tds
Study: 3530781
Drug: Bucindolol 100
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucindolol 100 mg
Study: 30837554
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive pill (COCP) exposure
Study: 24249840
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity telemonitoring program (n=40), wore a motion sensor continuously for 18 weeks, received weekly step count goals.
Study: 12040471
Drug: G-CSF starting
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF starting on day +1
Study: 12040471
Drug: G-CSF starting
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF starting on day +5
Study: 2521696
Drug: ANF infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANF infusion
Study: 23508277
Drug: 0.6 g
Normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g iodine/kg of TBW (n=33)
Study: 23508277
Drug: 0.75 g
Normalized name: Allantoin 0.75 g in 75 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 g iodine/kg of LBW (n=35)
Study: 23508277
Drug: 22 g
Normalized name: Empty Carpuject 2 mL 22 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 g iodine/m(2) BSA (n=35)
Study: 19324419
Drug: Olanzapine/Fluoxetine Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine/Fluoxetine Combination (OFC; 6/25, 6/50, or 12/50 mg/day)